$NTLA #ASH20 news: Lead immuno-oncology development candidate, NTLA-5001, shows high anti-tumor activity as promising #cancer treatment in proof-of-concept mouse models of acute leukemias. Details here: https://t.co/Z4PYUzoVke #CRISPR #AML #AcuteMyeloidLeukemia @ASH_hematology https://t.co/srkOIe3d08